JP2024516542A - Ｍｈｃクラスｉペプチドを含む方法および組成物 - Google Patents

Ｍｈｃクラスｉペプチドを含む方法および組成物 Download PDF

Info

Publication number
JP2024516542A
JP2024516542A JP2023561278A JP2023561278A JP2024516542A JP 2024516542 A JP2024516542 A JP 2024516542A JP 2023561278 A JP2023561278 A JP 2023561278A JP 2023561278 A JP2023561278 A JP 2023561278A JP 2024516542 A JP2024516542 A JP 2024516542A
Authority
JP
Japan
Prior art keywords
peptide
cells
cell
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516542A5 (https=
Inventor
サンチェス エドゥアルド ヴィラール
ウェンフイ ウー
クリシュナ エム． シンハ
カイル チャン
チャールズ エム． ボウエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2024516542A publication Critical patent/JP2024516542A/ja
Publication of JP2024516542A5 publication Critical patent/JP2024516542A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023561278A 2021-04-06 2022-04-06 Ｍｈｃクラスｉペプチドを含む方法および組成物 Pending JP2024516542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171137P 2021-04-06 2021-04-06
US63/171,137 2021-04-06
PCT/US2022/023714 WO2022216856A1 (en) 2021-04-06 2022-04-06 Methods and compositions comprising mhc class i peptides

Publications (2)

Publication Number Publication Date
JP2024516542A true JP2024516542A (ja) 2024-04-16
JP2024516542A5 JP2024516542A5 (https=) 2025-08-20

Family

ID=83546562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561278A Pending JP2024516542A (ja) 2021-04-06 2022-04-06 Ｍｈｃクラスｉペプチドを含む方法および組成物

Country Status (4)

Country Link
US (1) US20240218019A1 (https=)
EP (1) EP4320145A4 (https=)
JP (1) JP2024516542A (https=)
WO (1) WO2022216856A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240133853A (ko) * 2023-02-28 2024-09-05 루다큐어 주식회사 신규 펩타이드 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180088121A1 (en) * 2015-03-31 2018-03-29 Technische Universitaet Muenchen T cell receptors and peptides derived by mutations for the treatment of cancer
JP2018522822A (ja) * 2015-05-20 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
WO2018213803A1 (en) * 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
WO2019246315A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1430112A4 (en) * 2001-09-24 2005-06-15 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US8361780B2 (en) * 2005-06-30 2013-01-29 University Of Georgia Research Foundation, Inc. Biological system and assay for identifying modulators of tubulin ligases
US8791233B2 (en) * 2011-05-24 2014-07-29 Northwestern University Maspin-based peptides and methods of use thereof
FI3652606T3 (fi) * 2017-07-12 2023-03-16 Nouscom Ag Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180088121A1 (en) * 2015-03-31 2018-03-29 Technische Universitaet Muenchen T cell receptors and peptides derived by mutations for the treatment of cancer
JP2018522822A (ja) * 2015-05-20 2018-08-16 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
WO2018213803A1 (en) * 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
WO2019246315A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof

Also Published As

Publication number Publication date
WO2022216856A1 (en) 2022-10-13
US20240218019A1 (en) 2024-07-04
EP4320145A1 (en) 2024-02-14
EP4320145A4 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
JP7761293B2 (ja) Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
JP2021529753A (ja) 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法
TW201742873A (zh) 用於抗癌免疫治療的轉染t細胞及t細胞受體
US20240293459A1 (en) Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use
JP2024539291A (ja) 神経膠芽腫を治療するための方法および組成物
EP4247402A1 (en) Methods and compositions comprising mhc class i peptides
JP2024516542A (ja) Ｍｈｃクラスｉペプチドを含む方法および組成物
US20240207406A1 (en) Methods and compositions comprising mhc class i peptides
WO2025117509A1 (en) Recurrent neoantigen-related peptides and related compositions and methods
US20250352576A1 (en) Methods and compositions for treating gliomas
HK40100730A (zh) 包含mhc i类肽的方法和组合物
EP4711380A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
US20240382590A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof
HK40112339A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法
HK40113193A (zh) 靶向ndc80抗原的肽和经改造t细胞受体及使用方法
JP2024538169A (ja) Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
JP2024526836A (ja) Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
CN118103062A (zh) 靶向sars-cov-2抗原的肽和工程化t细胞受体及其使用方法
CN120380014A (zh) 靶向vcy抗原的肽和经改造t细胞受体及使用方法
HK40092477A (zh) 经改造t细胞受体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202